Presentation is loading. Please wait.

Presentation is loading. Please wait.

rSema4A increases the relative number of CD4+CD25+ HuT cells.

Published byOctavia McDowell Modified over 5 years ago

Similar presentations

Presentation on theme: "rSema4A increases the relative number of CD4+CD25+ HuT cells."— Presentation transcript:

1 rSema4A increases the relative number of CD4+CD25+ HuT cells.
rSema4A increases the relative number of CD4+CD25+ HuT cells. Cells were cultured in vitro in cRPMI with or without rSema4A for 48 h. Cells were analyzed for CD25 expression (A and B). Live HuT cell dot plots (A) and histograms (B) show the levels of CD25 marker expression. (B) Marker positivity on HuT cells in cultures with rSema4A is shown in black line with transparent background histograms or solid black color histogram (for 100 ng and 1 μg of rSema4A, correspondingly), whereas CD25 expression on cells cultured with medium alone is shown in solid gray color. Svetlana P. Chapoval et al. ImmunoHorizons 2019;3:71-87 Copyright © 2019 by The Authors

Download ppt "rSema4A increases the relative number of CD4+CD25+ HuT cells."

Similar presentations

NK cells inhibited the expansion and function of ILC2s in vitro via IFN-γ. NK cells inhibited the expansion and function of ILC2s in vitro via IFN-γ. ILC2s.

NK cells inhibited the expansion and function of ILC2s in vitro via IFN-γ. NK cells inhibited the expansion and function of ILC2s in vitro via IFN-γ. ILC2s.
Identification of combination treatment–responsive effector/memory tumor-infiltrating CD8+ T cell population. Identification of combination treatment–responsive.

Identification of combination treatment–responsive effector/memory tumor-infiltrating CD8+ T cell population. Identification of combination treatment–responsive.
Identification of combination treatment–responsive dysfunctional tumor-infiltrating CD8+ T cell population. Identification of combination treatment–responsive.

Identification of combination treatment–responsive dysfunctional tumor-infiltrating CD8+ T cell population. Identification of combination treatment–responsive.
MP cells, but not pathogen-elicited effector CD4+ T lymphocytes, rapidly produce IFN-γ during T. gondii infection independently of pathogen antigens. MP.

MP cells, but not pathogen-elicited effector CD4+ T lymphocytes, rapidly produce IFN-γ during T. gondii infection independently of pathogen antigens. MP.
Depletion of CD169+ cells leads to increased expression of CD25 on enterotoxin A–specific Vβ3+ T cells. Depletion of CD169+ cells leads to increased expression.

Depletion of CD169+ cells leads to increased expression of CD25 on enterotoxin A–specific Vβ3+ T cells. Depletion of CD169+ cells leads to increased expression.
Supplemental Figure 2, Ghielmetti et al

Supplemental Figure 2, Ghielmetti et al
MP cells are generated from naïve cells in the periphery.

MP cells are generated from naïve cells in the periphery.
Volume 141, Issue 3, Pages (September 2011)

Volume 141, Issue 3, Pages (September 2011)
Sven Y. Surikow et al. BTS 2018;3:

Sven Y. Surikow et al. BTS 2018;3:
Depo-Provera altered the expression of cell surface markers associated with HIV susceptibility. Depo-Provera altered the expression of cell surface markers.

Depo-Provera altered the expression of cell surface markers associated with HIV susceptibility. Depo-Provera altered the expression of cell surface markers.
rSema4A potentiates Treg cells in CD4+ T cell cultures.

rSema4A potentiates Treg cells in CD4+ T cell cultures.
Variable levels of cell surface and intracellular marker expression by HuT78 and HuT102 cells. Variable levels of cell surface and intracellular marker.

Variable levels of cell surface and intracellular marker expression by HuT78 and HuT102 cells. Variable levels of cell surface and intracellular marker.
TIGIT expression in naive T cells is accelerated by coculture with si-tolerant T cells at an early-stimulation stage. TIGIT expression in naive T cells.

TIGIT expression in naive T cells is accelerated by coculture with si-tolerant T cells at an early-stimulation stage. TIGIT expression in naive T cells.
Exposure to rSema4A increases Treg cell numbers in human PBMC in vitro cultures. Exposure to rSema4A increases Treg cell numbers in human PBMC in vitro.

Exposure to rSema4A increases Treg cell numbers in human PBMC in vitro cultures. Exposure to rSema4A increases Treg cell numbers in human PBMC in vitro.
rSema4A does not enhance Treg cell suppressive activity in vitro.

rSema4A does not enhance Treg cell suppressive activity in vitro.
Blocking of Plexin B1 before rSema4A applications decreases the relative numbers of Treg cells and IL-2 secretion in human PBMCs. Human anti–Plexin B1.

Blocking of Plexin B1 before rSema4A applications decreases the relative numbers of Treg cells and IL-2 secretion in human PBMCs. Human anti–Plexin B1.
Human Treg cells express PlexinB1.

Human Treg cells express PlexinB1.
rSema4A induces iTreg cells in CD4+ T cell cultures.

rSema4A induces iTreg cells in CD4+ T cell cultures.
Increased chemokine content and leukocyte infiltrate in D6-negative tumors. Increased chemokine content and leukocyte infiltrate in D6-negative tumors.

Increased chemokine content and leukocyte infiltrate in D6-negative tumors. Increased chemokine content and leukocyte infiltrate in D6-negative tumors.
rSema4A has no direct effect on Treg cells in the in vitro cultures.

rSema4A has no direct effect on Treg cells in the in vitro cultures.

Similar presentations

Ads by Google